State-of-the-art of the high dose influenza vaccine in Spain
-
By
-
Iván Sanz-Muñoz
-
Manel Farre-Avella
-
Paulo J. Barroso-Santos
-
José M. Eiros
-
June 30, 2026
-
Clinical Scorecard: Current Advances in High-Dose Influenza Vaccination in Spain
At a Glance
| Category | Detail |
|---|
| Condition | Influenza |
| Key Mechanisms | High-dose influenza vaccines enhance immune response in older adults, addressing immunosenescence and comorbidities. |
| Target Population | Adults aged ≥60 years |
| Care Setting | Vaccination strategies in community and institutional settings |
Key Highlights
- High-dose vaccines show superior effectiveness over standard-dose vaccines.
- Older adults are at increased risk for severe influenza complications.
- Evidence supports broader adoption of high-dose vaccines in Spain.
- Vaccination strategies vary across Spanish autonomous communities.
- Incorporation of high-dose vaccines marks a significant shift in national vaccination strategies.
Guideline-Based Recommendations
Diagnosis
- Consider influenza in older adults presenting with respiratory symptoms.
Management
- Administer high-dose influenza vaccines to adults aged ≥60 years.
Monitoring & Follow-up
- Monitor vaccination uptake and effectiveness across populations.
Risks
- Older adults with comorbidities face higher risks of severe influenza outcomes.
Patient & Prescribing Data
Adults aged ≥60 years, particularly those with comorbidities.
High-dose vaccines are recommended to enhance protection against severe influenza.
Clinical Best Practices
- Implement mixed vaccination strategies to include both institutionalized and community-dwelling older adults.
- Promote equitable access to high-dose influenza vaccines.
Related Resources & Content
